Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Cox

Showing results (621-630 of 676) with videos related to

Pageof 68
Sort By:
Oncotarget|October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsDavid G Cox, Elsa Curtit, Gilles Romieu, et al.
The Journal of Clinical Endocrinology and Metabolism|December 24, 2010
Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3)L Beckmann, A Hüsing, V W Setiawan, et al.
Breast Cancer Research : BCR|September 22, 2006
A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)David G Cox, Hélène Blanché, Celeste L Pearce, et al.
NPJ Breast Cancer|June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohortXavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
Nature Genetics|August 14, 2019
Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancerSahar Nissim, Ignaty Leshchiner, Joseph D Mancias, et al.
Plos One|March 5, 2011
Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)Daniele Campa, Anika Hüsing, Angelika Stein, et al.
Breast Cancer Research : BCR|August 24, 2017
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomesElsa Curtit, Xavier Pivot, Julie Henriques, et al.
Plos One|July 4, 2008
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)Alpa V Patel, Iona Cheng, Federico Canzian, et al.
International Journal of Cancer|October 16, 2007
Haplotypes of the estrogen receptor beta gene and breast cancer risk, David G Cox, Philip Bretsky, et al.
Cancer Research|April 6, 2007
A common 8q24 variant in prostate and breast cancer from a large nested case-control studyFredrick R Schumacher, Heather Spencer Feigelson, David G Cox, et al.
Pageof 68

Showing results (621-630 of 676) with videos related to

Sort By:
Pageof 68
Oncotarget|October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsDavid G Cox, Elsa Curtit, Gilles Romieu, et al.
The Journal of Clinical Endocrinology and Metabolism|December 24, 2010
Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3)L Beckmann, A Hüsing, V W Setiawan, et al.
Breast Cancer Research : BCR|September 22, 2006
A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)David G Cox, Hélène Blanché, Celeste L Pearce, et al.
NPJ Breast Cancer|June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohortXavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
Nature Genetics|August 14, 2019
Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancerSahar Nissim, Ignaty Leshchiner, Joseph D Mancias, et al.
Plos One|March 5, 2011
Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)Daniele Campa, Anika Hüsing, Angelika Stein, et al.
Breast Cancer Research : BCR|August 24, 2017
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomesElsa Curtit, Xavier Pivot, Julie Henriques, et al.
Plos One|July 4, 2008
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)Alpa V Patel, Iona Cheng, Federico Canzian, et al.
International Journal of Cancer|October 16, 2007
Haplotypes of the estrogen receptor beta gene and breast cancer risk, David G Cox, Philip Bretsky, et al.
Cancer Research|April 6, 2007
A common 8q24 variant in prostate and breast cancer from a large nested case-control studyFredrick R Schumacher, Heather Spencer Feigelson, David G Cox, et al.
Pageof 68